Phase II trial of alternating courses of @entity6303 and @entity440 in advanced XXXX : a Gynecologic Oncology Group study.

@entity1 @entity1204 @entity137 @entity440 @entity5 @entity5353 @entity530 @entity6303 @entity1031 @entity8218
OBJECTIVES: To estimate the objective response rate and @entity137 associated with alternating @entity6303 (MA) and @entity440 (T) in @entity1 with @entity1204 . METHODS: Consenting @entity1 with measurable recurrent or advanced @entity1204 were eligible if they had not received prior cytotoxic or hormonal treatment. MA 80 mg @entity5353 x 3 weeks alternating with T 20 mg @entity5353 x 3 weeks orally was given. RESULTS: Of 61 @entity1 entered, 56 eligible @entity1 were evaluable for @entity137 and response. Fifteen @entity1 responded (12 complete, 3 partial) for an overall response rate of 27% (90% Confidence Interval: 17-38%). In 8 of 15 (53%) responders, response duration exceeded 20 months. The response rate was 38% in @entity1 with histologic grade 1 @entity5 (n = 16), 24% in those with grade 2 disease (n = 17), and 22% among @entity1 with grade 3 disease (n = 23). @entity1 less than or equal to 60 years (n = 16) appear to have a better response rate than those >60 years (n = 40), 44% versus 20%. The response rate in @entity1 with extra @entity530 (n = 42) was 31% as compared to 14% in those with strictly pelvic and/or @entity8218 (n = 14). The median progression-free survival (PFS) was 2.7 months and median overall survival was 14.0 months. Two @entity1 experienced a grade 4 @entity1031 event. Additional @entity137 included one of each grade 3 gastrointestinal, grade 3 neurologic, and grade 3 genitourinary. CONCLUSION: A regimen of alternating @entity6303 and @entity440 is active in treating @entity1204 and may result in a prolonged complete response (CR) in some @entity1 .
